4.6 Review

Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID-19): Are they similar?

Journal

TRANSBOUNDARY AND EMERGING DISEASES
Volume 68, Issue 4, Pages 1786-1799

Publisher

WILEY-HINDAWI
DOI: 10.1111/tbed.13856

Keywords

COVID-19; feline coronavirus; feline infectious peritonitis; SARS-CoV-2

Ask authors/readers for more resources

Feline infectious peritonitis (FIP) and COVID-19, caused by coronaviruses, share some similar pathogenic and immunopathogenic events. Preventive measures recommended for preventing SARS-CoV-2 spread have also shown success in eradicating FIP in feline households. Additionally, the therapeutic compound GS-441524, effective against FIP, is the active form of Remdesivir used as a therapeutic option for COVID-19.
SARS-CoV-2 has radically changed our lives causing hundreds of thousands of victims worldwide and influencing our lifestyle and habits. Feline infectious peritonitis (FIP) is a disease of felids caused by the feline coronaviruses (FCoV). FIP has been considered irremediably deadly until the last few years. Being one of the numerous coronaviruses that are well known in veterinary medicine, information on FCoV could be of interest and might give suggestions on pathogenic aspects of SARS-CoV-2 that are still unclear. The authors of this paper describe the most important aspects of FIP and COVID-19 and the similarities and differences between these important diseases. SARS-CoV-2 and FCoV are taxonomically distant viruses, and recombination events with other coronaviruses have been reported for FCoV and have been suggested for SARS-CoV-2. SARS-CoV-2 and FCoV differ in terms of some pathogenic, clinical and pathological features. However, some of the pathogenic and immunopathogenic events that are well known in cats FIP seem to be present also in people with COVID-19. Moreover, preventive measures currently recommended to prevent SARS-CoV-2 spreading have been shown to allow eradication of FIP in feline households. Finally, one of the most promising therapeutic compounds against FIP, GS-441524, is the active form of Remdesivir, which is being used as one therapeutic option for COVID-19.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available